Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer
Ayers M, Symmans W, Stec J, Damokosh A, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi G, Pusztai L. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer. Journal Of Clinical Oncology 2004, 22: 2284-2293. PMID: 15136595, DOI: 10.1200/jco.2004.05.166.Peer-Reviewed Original ResearchConceptsPathologic complete responseBreast cancerNeoadjuvant therapyClinical resultsPredictive valueCompletion of chemotherapySequential weekly paclitaxelComplete pathologic responseNeoadjuvant chemotherapy regimenPercent of patientsPatients' clinical resultsExpected response rateFine-needle aspirationNegative predictive valuePositive predictive valueNeoadjuvant paclitaxelChemotherapy regimenWeekly paclitaxelCyclophosphamide chemotherapyUnselected patientsComplete responsePathologic responseInvasive cancerResponse ratePatients